Cargando…
TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p
SIMPLE SUMMARY: An estimated ~25–30% of patients with advanced prostate cancer (PCa) develop the aggressive and lethal form of the disease known as treatment-induced neuroendocrine prostate cancer (t-NEPC). Owing to lack of treatment options, the identification of the underlying molecular mechanisms...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507954/ https://www.ncbi.nlm.nih.gov/pubmed/34638504 http://dx.doi.org/10.3390/cancers13195020 |
_version_ | 1784581982141808640 |
---|---|
author | Patel, Girijesh Kumar Dutta, Sayanika Mahmud Syed, Mosharaf Ramachandran, Sabarish Sharma, Monica Rajamanickam, Venkatesh Ganapathy, Vadivel DeGraff, David J. Pruitt, Kevin Tripathi, Manisha Nandana, Srinivas |
author_facet | Patel, Girijesh Kumar Dutta, Sayanika Mahmud Syed, Mosharaf Ramachandran, Sabarish Sharma, Monica Rajamanickam, Venkatesh Ganapathy, Vadivel DeGraff, David J. Pruitt, Kevin Tripathi, Manisha Nandana, Srinivas |
author_sort | Patel, Girijesh Kumar |
collection | PubMed |
description | SIMPLE SUMMARY: An estimated ~25–30% of patients with advanced prostate cancer (PCa) develop the aggressive and lethal form of the disease known as treatment-induced neuroendocrine prostate cancer (t-NEPC). Owing to lack of treatment options, the identification of the underlying molecular mechanisms that propagate the t-NEPC phenotype is critical towards developing novel therapeutic strategies against advanced PCa. Further, the roles of extracellular vesicles (exosomes) and microRNAs—an increasingly recognized and key mode of propagation of the NEPC phenotype—remain elusive. Our studies reveal that TBX2 promotes SOX2- and N-MYC- driven t-NEPC through regulation of the intermediary factor—miR-200c-3p; and that TBX2/miR-200c-3p/SOX2/MYCN signaling can promote t-NEPC via both intracellular and exosome-mediated intercellular mechanisms. ABSTRACT: Deciphering the mechanisms that drive transdifferentiation to neuroendocrine prostate cancer (NEPC) is crucial to identifying novel therapeutic strategies against this lethal and aggressive subtype of advanced prostate cancer (PCa). Further, the role played by exosomal microRNAs (miRs) in mediating signaling mechanisms that propagate the NEPC phenotype remains largely elusive. The unbiased differential miR expression profiling of human PCa cells genetically modulated for TBX2 expression led to the identification of miR-200c-3p. Our findings have unraveled the TBX2/miR-200c-3p/SOX2/N-MYC signaling axis in NEPC transdifferentiation. Mechanistically, we found that: (1) TBX2 binds to the promoter and represses the expression of miR-200c-3p, a miR reported to be lost in castrate resistant prostate cancer (CRPC), and (2) the repression of miR-200c-3p results in the increased expression of its targets SOX2 and N-MYC. In addition, the rescue of mir-200c-3p in the context of TBX2 blockade revealed that miR-200c-3p is the critical intermediary effector in TBX2 regulation of SOX2 and N-MYC. Further, our studies show that in addition to the intracellular mode, TBX2/miR-200c-3p/SOX2/N-MYC signaling can promote NEPC transdifferentiation via exosome-mediated intercellular mechanism, an increasingly recognized and key mode of propagation of the NEPC phenotype. |
format | Online Article Text |
id | pubmed-8507954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85079542021-10-13 TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p Patel, Girijesh Kumar Dutta, Sayanika Mahmud Syed, Mosharaf Ramachandran, Sabarish Sharma, Monica Rajamanickam, Venkatesh Ganapathy, Vadivel DeGraff, David J. Pruitt, Kevin Tripathi, Manisha Nandana, Srinivas Cancers (Basel) Article SIMPLE SUMMARY: An estimated ~25–30% of patients with advanced prostate cancer (PCa) develop the aggressive and lethal form of the disease known as treatment-induced neuroendocrine prostate cancer (t-NEPC). Owing to lack of treatment options, the identification of the underlying molecular mechanisms that propagate the t-NEPC phenotype is critical towards developing novel therapeutic strategies against advanced PCa. Further, the roles of extracellular vesicles (exosomes) and microRNAs—an increasingly recognized and key mode of propagation of the NEPC phenotype—remain elusive. Our studies reveal that TBX2 promotes SOX2- and N-MYC- driven t-NEPC through regulation of the intermediary factor—miR-200c-3p; and that TBX2/miR-200c-3p/SOX2/MYCN signaling can promote t-NEPC via both intracellular and exosome-mediated intercellular mechanisms. ABSTRACT: Deciphering the mechanisms that drive transdifferentiation to neuroendocrine prostate cancer (NEPC) is crucial to identifying novel therapeutic strategies against this lethal and aggressive subtype of advanced prostate cancer (PCa). Further, the role played by exosomal microRNAs (miRs) in mediating signaling mechanisms that propagate the NEPC phenotype remains largely elusive. The unbiased differential miR expression profiling of human PCa cells genetically modulated for TBX2 expression led to the identification of miR-200c-3p. Our findings have unraveled the TBX2/miR-200c-3p/SOX2/N-MYC signaling axis in NEPC transdifferentiation. Mechanistically, we found that: (1) TBX2 binds to the promoter and represses the expression of miR-200c-3p, a miR reported to be lost in castrate resistant prostate cancer (CRPC), and (2) the repression of miR-200c-3p results in the increased expression of its targets SOX2 and N-MYC. In addition, the rescue of mir-200c-3p in the context of TBX2 blockade revealed that miR-200c-3p is the critical intermediary effector in TBX2 regulation of SOX2 and N-MYC. Further, our studies show that in addition to the intracellular mode, TBX2/miR-200c-3p/SOX2/N-MYC signaling can promote NEPC transdifferentiation via exosome-mediated intercellular mechanism, an increasingly recognized and key mode of propagation of the NEPC phenotype. MDPI 2021-10-07 /pmc/articles/PMC8507954/ /pubmed/34638504 http://dx.doi.org/10.3390/cancers13195020 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Patel, Girijesh Kumar Dutta, Sayanika Mahmud Syed, Mosharaf Ramachandran, Sabarish Sharma, Monica Rajamanickam, Venkatesh Ganapathy, Vadivel DeGraff, David J. Pruitt, Kevin Tripathi, Manisha Nandana, Srinivas TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p |
title | TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p |
title_full | TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p |
title_fullStr | TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p |
title_full_unstemmed | TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p |
title_short | TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p |
title_sort | tbx2 drives neuroendocrine prostate cancer through exosome-mediated repression of mir-200c-3p |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507954/ https://www.ncbi.nlm.nih.gov/pubmed/34638504 http://dx.doi.org/10.3390/cancers13195020 |
work_keys_str_mv | AT patelgirijeshkumar tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p AT duttasayanika tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p AT mahmudsyedmosharaf tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p AT ramachandransabarish tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p AT sharmamonica tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p AT rajamanickamvenkatesh tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p AT ganapathyvadivel tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p AT degraffdavidj tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p AT pruittkevin tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p AT tripathimanisha tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p AT nandanasrinivas tbx2drivesneuroendocrineprostatecancerthroughexosomemediatedrepressionofmir200c3p |